One Wales Medicines interim decisions

Mepolizumab (Nucala®) for chronic eosinophilic pneumonia (OW15): Last review date: 17/05/2022

Rituximab for pemphigus and pemphigoid (OW10): Last review date: 17/05/2022

Sorafenib for acute myeloid leukaemia (AML) maintenance (OW18): Issue date; 14/04/2022

Rituximab for interstitial lung disease (OW13): Last review date: 29/12/2021

Rituximab for myasthenia gravis (OW12): Last review date: 29/12/2021

Bevacizumab for ovarian cancer (OW01): Last review date: 29/09/2021

Bendamustine and rituximab for indolent lymphomas (OW08): Last review date: 29/09/2021

Bendamustine and rituximab for mantle cell lymphoma (OW09): Last review date: 29/09/2021

Adalimumab for paediatric intermediate, posterior and pan-uveitis (OW04): Last review date: 26/07/2021

Arsenic trioxide for high risk acute promyelocytic leukaemia (OW06): Last review date: 26/07/2021

Azacitidine for progressive angioimmunoblastic T-cell lymphoma (OW16): Last review date: 26/07/2021

Abiraterone acetate (Zytiga®) for prostate cancer (OW17): Last update: 16/07/2021

Denosumab (Prolia®) for osteoporosis in men (OW07): Last review date: 11/12/2021

Follow AWTTC: